129 related articles for article (PubMed ID: 23074114)
1. Immunophenotypes of glycogen rich clear cell carcinoma.
Kim SE; Koo JS; Jung WH
Yonsei Med J; 2012 Nov; 53(6):1142-6. PubMed ID: 23074114
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic characteristics and prognosis of glycogen-rich clear cell carcinoma of the breast.
Ma X; Han Y; Fan Y; Cao X; Wang X
Breast J; 2014; 20(2):166-73. PubMed ID: 24400866
[TBL] [Abstract][Full Text] [Related]
3. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
4. Glycogen-rich Clear Cell Carcinoma of the Breast: A Comprehensive Review.
Vranic S; Skenderi F; Beslagic V; Gatalica Z
Appl Immunohistochem Mol Morphol; 2020 Oct; 28(9):655-660. PubMed ID: 32167940
[TBL] [Abstract][Full Text] [Related]
5. EGFR, HER-2/neu, cyclin D1, p21 and p53 in correlation to cell proliferation and steroid hormone receptor status in ductal carcinoma in situ of the breast.
Lebeau A; Unholzer A; Amann G; Kronawitter M; Bauerfeind I; Sendelhofert A; Iff A; Löhrs U
Breast Cancer Res Treat; 2003 May; 79(2):187-98. PubMed ID: 12825853
[TBL] [Abstract][Full Text] [Related]
6. Triple-negative breast cancer: current state of the art.
Rastelli F; Biancanelli S; Falzetta A; Martignetti A; Casi C; Bascioni R; Giustini L; Crispino S
Tumori; 2010; 96(6):875-88. PubMed ID: 21388048
[TBL] [Abstract][Full Text] [Related]
7. Histopathological and immunohistochemical findings in a case of glycogen-rich clear cell carcinoma of the breast.
Takekawa Y; Kubo A; Morita T; Kameda K; Kimura M; Sakakibara M; Yoshii R; Yamashita Y
Rinsho Byori; 2006 Jan; 54(1):27-30. PubMed ID: 16499226
[TBL] [Abstract][Full Text] [Related]
8. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression.
Lax SF; Pizer ES; Ronnett BM; Kurman RJ
Hum Pathol; 1998 Jun; 29(6):551-8. PubMed ID: 9635673
[TBL] [Abstract][Full Text] [Related]
9. Clinical and pathological features of glycogen-rich clear cell carcinoma of the breast.
Kuroda H; Sakamoto G; Ohnisi K; Itoyama S
Breast Cancer; 2005; 12(3):189-95. PubMed ID: 16110288
[TBL] [Abstract][Full Text] [Related]
10. Oestrogen receptor negativity as a marker for high-grade ductal carcinoma in situ of the breast.
Baqai T; Shousha S
Histopathology; 2003 May; 42(5):440-7. PubMed ID: 12713620
[TBL] [Abstract][Full Text] [Related]
11. Fine needle aspiration cytology of glycogen-rich clear cell carcinoma of the breast: review of 37 cases with histologic correlation.
Akbulut M; Zekioglu O; Kapkac M; Erhan Y; Ozdemir N
Acta Cytol; 2008; 52(1):65-71. PubMed ID: 18323277
[TBL] [Abstract][Full Text] [Related]
12. Prognostic variables in invasive breast cancer: contribution of comedo versus noncomedo in situ component.
Brower ST; Ahmed S; Tartter PI; Bleiweiss I; Amberson JB
Ann Surg Oncol; 1995 Sep; 2(5):440-4. PubMed ID: 7496840
[TBL] [Abstract][Full Text] [Related]
13. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
[TBL] [Abstract][Full Text] [Related]
14. Histological and immunohistochemical features of medullary breast cancer.
Romaniuk A; Lyndin M; Sikora V; Lyndina Y; Panasovska K
Folia Med Cracov; 2015; 55(2):41-8. PubMed ID: 26839242
[TBL] [Abstract][Full Text] [Related]
15. ER-/PR+/HER2- breast cancer type shows the highest proliferative activity among all other combined phenotypes and is more common in young patients: Experience with 6643 breast cancer cases.
Arena V; Pennacchia I; Vecchio FM; Carbone A
Breast J; 2019 May; 25(3):381-385. PubMed ID: 30916428
[TBL] [Abstract][Full Text] [Related]
16. Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-α expression in invasive ductal breast cancer patients and correlations with prognosis.
Yan J; Liu XL; Han LZ; Xiao G; Li NL; Deng YN; Yin LC; Ling LJ; Yu XY; Tan CL; Huang XP; Liu LX
Asian Pac J Cancer Prev; 2015; 16(2):823-9. PubMed ID: 25684532
[TBL] [Abstract][Full Text] [Related]
17. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
[TBL] [Abstract][Full Text] [Related]
18. Role of Melatonin in Breast Carcinoma: Correlation of Expression Patterns of Melatonin-1 Receptor With Estrogen, Progesterone, and HER2 Receptors.
Goyal R; Gupta T; Bal A; Sahni D; Singh G
Appl Immunohistochem Mol Morphol; 2020 Aug; 28(7):518-523. PubMed ID: 31290783
[TBL] [Abstract][Full Text] [Related]
19. Subtypes of Breast Cancer in Lao P.D.R.: A Study in a Limited-Resource Setting.
Luangxay T; Virachith S; Hando K; Vilayvong S; Xaysomphet P; Arounlangsy P; Phongsavan K; Mieno MN; Honma N; Kitagawa M; Sawabe M
Asian Pac J Cancer Prev; 2019 Feb; 20(2):589-594. PubMed ID: 30806064
[TBL] [Abstract][Full Text] [Related]
20. Correlation of E-cadherin expression and routine immunohistochemistry panel in breast invasive ductal carcinoma.
Mohammadizadeh F; Ghasemibasir H; Rajabi P; Naimi A; Eftekhari A; Mesbah A
Cancer Biomark; 2009; 5(1):1-8. PubMed ID: 19242056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
